RYTM Stock Analysis: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$90.52
-3.11 (-3.32%)
▼
5d:
-3.88%
30d:
+2.74%
90d:
-7.7%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
RYTM is down 3.9% this week, but smart money is accumulating calls. Top strike: $90 2026-06-18 with 44 OI. Call ratio: 100% View Scanner →
Strength: 6.9/10
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RYTM this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RYTM shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: RYTM shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $90.52, which is considered slightly high relative to its 30-day fair value range of $83.72 to $91.88.
Technical Outlook: Technically, RYTM is in a strong downtrend. Immediate support is located at $81.09, while resistance sits at $99.00. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: RYTM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $138.20 (+52.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RYTM is in a strong downtrend. Immediate support is located at $81.09, while resistance sits at $99.00. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: RYTM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $138.20 (+52.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$83.72 -
$91.88
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 52.7% below Wall St target ($138.20)
Trading Range Analysis
30-Day Trading Range
$83.72 -
$91.88
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$8.85
(9.8%)
Support & Resistance Levels
Support Level
$81.09
Resistance Level
$99.00
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-79.63
Wall Street Target
$138.20
(+52.7%)
Revenue Growth (YoY)
83.8%
Profit Margin
-93.3%
Share & Embed Analysis
Last updated: May 16, 2026 12:48 AM ET
Data refreshes hourly during market hours. Next update: 1:48 AM
Data refreshes hourly during market hours. Next update: 1:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Paul German
SELL
5614 shares
2026-03-04
Hunter C Smith
SELL
4385 shares
2026-02-19
Hunter C Smith
SELL
3569 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 60 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 42 HOLD |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
